SCHEMBL5545808

SCHEMBL5545808

CCOC(=O)c1ncc(Cc2ccc(F)cc2)cc1NCCCN1CCCCC1=O

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.43
MAPT P10636 1/20 0.43
RAB9A P51151 2/20 0.42
PDE3B Q13370 1/20 0.41
PDE3A Q14432 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
CYP2C19 P33261 2/20 0.40
KDM4E B2RXH2 1/20 0.39
CYP1A2 P05177 1/20 0.39
TSHR P16473 2/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
GAA P10253 1/20 0.39
FSHR P23945 1/20 0.39
NPC1 O15118 2/20 0.39
ATM Q13315 1/20 0.39
SIRT2 Q8IXJ6 1/20 0.38
SIRT1 Q96EB6 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5540809 0.99 ALDH1A1 (0.43) ALDH1A1MAPTRAB9APDE3BPDE3A
SCHEMBL5543117 0.98 ALDH1A1 (0.45) ALDH1A1MAPTRAB9APDE3BPDE3A
SCHEMBL4718288 0.93 PDE3B (0.44) ALDH1A1MAPTRAB9APDE3BPDE3A
SCHEMBL5546436 0.82 RAB9A (0.41) ALDH1A1MAPTRAB9APDE3BPDE3A
SCHEMBL5538835 0.82 PDE3B (0.38) ALDH1A1MAPTRAB9APDE3BPDE3A
SCHEMBL5545570 0.81 ALDH1A1 (0.43) ALDH1A1MAPTSMN1; SMN2CYP2C19KDM4E
SCHEMBL5540769 0.81 MEN1 (0.37) ALDH1A1MAPTRAB9APDE3BPDE3A
SCHEMBL5538851 0.81 PDE3B (0.38) ALDH1A1MAPTRAB9APDE3BPDE3A
SCHEMBL5538668 0.80 PDE3B (0.40) ALDH1A1MAPTRAB9APDE3BPDE3A
SCHEMBL5541233 0.80 PDE3B (0.37) ALDH1A1MAPTRAB9APDE3BPDE3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150225399-A1 HIV INTEGRASE INHIBITORS VIIV HEALTHCARE CO (US) 2015-08-13 US disclosed
US-20140256713-A1 2-OXONAPHTHYRIDINE-3-CARBOXAMIDES HIV INTEGRASE INHIBITORS SHIONOGI & CO., LTD. (JP) 2014-09-11 US disclosed
EP-1720856-B1 HIV INTEGRASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2013-08-14 EP disclosed
US-20070124152-A1 Hiv Integrase Inhibitors GLAXOSMITHKLINE LLC 2007-05-31 US disclosed
EP-1720856-A2 HIV INTEGRASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2006-11-15 EP disclosed
WO-2005077050-A2 HIV INTEGRASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2005-08-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140256713-A1 2-OXONAPHTHYRIDINE-3-CARBOXAMIDES HIV INTEGRASE INHIBITORS BCDIN3D, DUT, SAMHD1 ALDH1A1 3812/4885MAPT 2173/4885RAB9A 2184/4885
US-20150225399-A1 HIV INTEGRASE INHIBITORS ING2, API5, SAMHD1 ALDH1A1 3073/4885MAPT 949/4885RAB9A 2632/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.